tradingkey.logo

tradingkey.logo
怜玢


Bioventus Inc

BVS
りォッチリストに远加
12.910USD
+0.280+2.22%
終倀 09-17 16:00ET
879.25M時䟡総額
30.16盎近12ヶ月PER

詳现情報 Bioventus Inc 䌁業名

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

Bioventus Inc プロフィヌル


䌁業コヌドBVS
䌚瀟名Bioventus Inc
䞊堎日Feb 11, 2021
最高経営責任者「CEO」Claypoole (Robert E)
埓業員数930
蚌刞皮類Ordinary Share
決算期末Feb 11
本瀟所圚地4721 Emperor Boulevard, Suite 100
郜垂DURHAM
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号27703
電話番号19194746700
りェブサむトhttps://www.bioventus.com/
䌁業コヌドBVS
䞊堎日Feb 11, 2021
最高経営責任者「CEO」Claypoole (Robert E)

Bioventus Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%

よくある質問

Bioventus Incの䞊䜍5名の株䞻は誰ですか


Bioventus Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Anthony (Tony) D'Adamio, J.D.

Bioventus IncBVSの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Bioventus Incの株匏を保有しおいる機関は339瀟あり、保有株匏の総垂堎䟡倀は玄52.51Mで、党䜓の77.51%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-10203484.00増加しおいたす。

Bioventus Incの最倧の収益源は䜕ですか


2026Q1においお、Pain Treatments郚門がBioventus Incにずっお最倧の収益を生み出しおおり、その金額は81.75Mで、党収益の53.36%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。